We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

99 hedge funds and large institutions have $747M invested in Autolus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,157% more call options, than puts

Call options by funds: $1.52M | Put options by funds: $21K

580% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 5

189% more capital invested

Capital invested by funds: $258M → $747M (+$489M)

39% more funds holding

Funds holding: 71 → 99 (+28)

11% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 19

2.67% more ownership

Funds ownership: 64% → 66.67% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
99
Holders Change
+28
Holders Change %
+39.44%
% of All Funds
1.44%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
34
Increased
21
Reduced
19
Closed
5
Calls
$1.52M
Puts
$21K
Net Calls
+$1.5M
Net Calls Change
+$1.14M

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$19.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$14.6M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.4M
4
PA
Perceptive Advisors
New York
+$6.98M
5
FAM
Fred Alger Management
New York
+$5.17M

Top Sellers

Rank Fund Capital Flow
1
TAM
TFG Asset Management
Cayman Islands
-$15.3M
2
DTC
Deep Track Capital
Connecticut
-$11.9M
3
AC
Armistice Capital
New York
-$11.6M
4
PBA
Paradigm Biocapital Advisors
New York
-$6.85M
5
DCM
DAFNA Capital Management
California
-$2.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBV
76
United Bank (Virginia)
Virginia
$74.1K – – –
Lazard Asset Management
77
Lazard Asset Management
New York
$74K +$2.02K +531 +5%
EC
78
EntryPoint Capital
New York
$64.9K +$38.5K +10,084 New
Invesco
79
Invesco
Georgia
$64.9K -$900 -236 -2%
TRCT
80
Tower Research Capital (TRC)
New York
$63.1K -$30.1K -7,903 -45%
BNP Paribas Financial Markets
81
BNP Paribas Financial Markets
France
$27.5K +$12.6K +3,292 +337%
CM
82
Caption Management
Oklahoma
$24.2K +$14.3K +3,759 New
QCG
83
Quadrant Capital Group
Ohio
$19.5K – – –
BAM
84
Byrne Asset Management
New Jersey
$17.9K +$10.3K +2,700 New
Citigroup
85
Citigroup
New York
$16.4K +$9.71K +2,545 New
Fidelity Investments
86
Fidelity Investments
Massachusetts
$14.3K – – –
Qube Research & Technologies (QRT)
87
Qube Research & Technologies (QRT)
United Kingdom
$12.6K -$31.7K -8,315 -81%
LC
88
Lindbrook Capital
California
$12.5K – – –
US Bancorp
89
US Bancorp
Minnesota
$8.91K +$5.28K +1,384 New
RhumbLine Advisers
90
RhumbLine Advisers
Massachusetts
$7.39K – – –
NS
91
NBC Securities
Alabama
$5K – – –
Daiwa Securities Group
92
Daiwa Securities Group
Japan
$4K +$2.19K +575 New
CHA
93
Carmichael Hill & Associates
Maryland
$3.27K – – –
CAM
94
Close Asset Management
United Kingdom
$3K – – –
GI
95
GAMMA Investing
California
$1.85K +$1.17K +307 New
PFBT
96
Parkside Financial Bank & Trust
Missouri
$1.29K +$763 +200 New
CPG
97
Cornerstone Planning Group
New Jersey
$644 – – –
HNB
98
Huntington National Bank
Ohio
$6 – – –
AA
99
ALPS Advisors
Colorado
– -$299K -128,147 Closed
BRWA
100
B. Riley Wealth Advisors
Florida
– -$39.6K -17,000 Closed
1 2 3
4
5

AUTL Hedge Fund Activity: Q4 2023 in Review

99 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2023, worth a combined $747M — up 189% from $258M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new AUTL positions and 5 closed out — a net gain of 29 holders — while 21 added to existing stakes and 19 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $19.3M. The largest seller was TFG Asset Management, cutting an estimated $15.3M.

  • 99 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2023, up from 71 in Q3 2023.
  • Funds reported $747M of Autolus Therapeutics stock for Q4 2023, up 189% quarter-over-quarter.
  • 34 funds opened new Autolus Therapeutics positions in Q4 2023 and 5 closed out, a net change of +29 holders.
  • The largest Autolus Therapeutics buyer in Q4 2023 was Cormorant Asset Management, an estimated $19.3M added.
  • The largest Autolus Therapeutics seller in Q4 2023 was TFG Asset Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q4 2023.